CagriSema Awaits an FDA Decision. Here Is What the Trials Show, and What Only Novo Has Said

What happened / Why it matters

What happened. Novo Nordisk says it filed a New Drug Application with FDA in December 2025 for CagriSema, an investigational combination of cagrilintide and semaglutide, for weight management, and that a decision is expected in the fourth quarter of 2026. That is the company’s statement. We did not find an official FDA action date, and CagriSema is not approved for any use.

Why it matters. Several headline numbers for CagriSema come from Novo’s own announcements, not from peer-reviewed papers, and they are easy to misread. This article separates what we found published from what is company-reported only.

What has been published?

The two published phase 3 trials in weight management, both in the New England Journal of Medicine:

The REDEFINE 1 abstract also reports gastrointestinal side effects in 79.6% of the CagriSema group versus 39.9% on placebo. Novo’s own release on the trial lists nausea in 55% versus 12.6%, constipation in 30.7% versus 11.6%, and vomiting in 26.1% versus 4.1%, mostly transient and mild to moderate, and stopping because of side effects in 5.9% versus 3.5%.

The published REDEFINE 1 figure is 20.4%. Higher figures you may see are from other analyses, explained below.

Three REIMAGINE trials of CagriSema in type 2 diabetes are also published, focused on blood sugar: REIMAGINE 1, REIMAGINE 2 and REIMAGINE 3. We do not report their results here.

What is known only from Novo’s announcements?

None of the following results, as far as we could find, has been published in a peer-reviewed journal.

Does CagriSema beat tirzepatide?

Not as a general statement. The answer depends on the dose of tirzepatide and the trial:

• Against tirzepatide 5 mg in people with type 2 diabetes (REIMAGINE 5), Novo reports CagriSema was superior for weight loss.
• Against tirzepatide 15 mg in people with obesity (REDEFINE 4), Novo reports CagriSema did not meet the non-inferiority goal, and tirzepatide’s average weight loss was numerically higher under both analyses.

These are two different trials, populations, durations and comparator doses, and neither is peer-reviewed. Novo says a third trial, REIMAGINE 4, also compared CagriSema with tirzepatide. We have not reviewed its results. A claim that CagriSema “beats tirzepatide” without naming the dose is not supported.

Is “25% weight loss in women” a trial result?

No. The 25.0% figure comes from a post hoc analysis, meaning one planned after the trial ended, and it uses the efficacy estimand, which estimates the effect had all participants stayed on treatment. Pharmacy Times (a secondary source) cautions that such figures are not directly comparable with the primary published result. For all participants in REDEFINE 1, the published result is 20.4%.

What is CagriSema’s regulatory status?

• Not approved. A search of FDA’s Drugs@FDA data on Oct. 30 found no product listed under that name. Novo says it filed its application in December 2025 and expects a decision in Q4 2026. We found no official action date. We saw no filing for type 2 diabetes in the material we reviewed.
• Not allowed in compounding. FDA states that cagrilintide and retatrutide “cannot be used in compounding under federal law.” Cagrilintide is not among the six peptides in the HHS interim policy published Oct. 30.
• Cagrilintide alone is not CagriSema. The combination contains semaglutide, which is approved on its own; cagrilintide is not approved.

What is still unknown?

The long-term safety of the combination, FDA’s decision and its timing, and whether the company-reported trials hold up when published and reviewed. Anyone considering weight-loss treatment should talk with a clinician about approved options and the evidence for each. We do not link to or recommend sellers.

Regulatory status verified Oct. 31, 2026. A decision is expected within the quarter; we will update this article with a visible note when FDA acts.